1522 studies found for:    Blood Coagulation Disorders: Clinical Trials
Show Display Options
Rank Status Study
21 Completed Hemodilution and Coagulopathy With 3 Colloids
Condition: Dilutional Coagulopathy
Intervention: Other: Induced Coagulopathy by HES (Tetraspan), Gelatin (Physiogel), Gelatin balanced (Physiogel balanced)
22 Completed
Has Results
Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: vatreptacog alfa (activated);   Drug: eptacog alfa (activated)
23 Completed Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Other: factor IX;   Drug: factor VIII
24 Active, not recruiting Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency
Intervention: Drug: catridecacog
25 Active, not recruiting Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa
26 Completed Changes in Oral Vitamin K Intake for Optimization of Chronic Oral Anticoagulation: A Randomized Trial
Condition: Blood Coagulation Disorders
Intervention: Behavioral: Changes on Oral Vitamin K Intake
27 Completed Safety and Efficacy of NNC-0156-0000-0009 After Long-Term Exposure in Patients With Haemophilia B: An Extension to Trials NN7999-3747 and NN7999-3773
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
28 Completed A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia A With Inhibitors;   Haemophilia B;   Haemophilia B With Inhibitors
Intervention: Drug: eptacog alfa (activated)
29 Active, not recruiting Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
30 Completed Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State
Conditions: Congenital Bleeding Disorder;   Haemophilia A;   Haemophilia B
Intervention: Drug: activated recombinant human factor VII
31 Completed
Has Results
Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency
Conditions: Congenital Bleeding Disorder;   Congenital FXIII Deficiency
Intervention: Drug: catridecacog
32 Completed
Has Results
Trial to Evaluate the Efficacy and Safety of a New Full Length Recombinant Human FVIII for Hemophilia A
Conditions: Blood Coagulation Disorders;   Hemophilia A
Interventions: Biological: Recombinant Factor VIII (BAY81-8973);   Biological: Recombinant Factor VIII (Kogenate FS, BAY14-2222)
33 Completed Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Interventions: Drug: turoctocog alfa 2000 IU/vial;   Drug: turoctocog alfa 3000 IU/vial
34 Active, not recruiting Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B
Conditions: Congenital Bleeding Disorder;   Haemophilia B
Intervention: Drug: NNC-0156-0000-0009
35 Terminated
Has Results
Evaluation of Recombinant Factor VIIa in Patients With Severe Bleeding
Conditions: Acquired Bleeding Disorder;   Trauma
Interventions: Drug: eptacog alfa (activated);   Drug: placebo
36 Completed Fibrinogen Concentrate In Children After Cardiac Surgery
Conditions: Cardiac Surgical Procedures;   Blood Coagulation Disorders;   Fibrinogen;   Cryoprecipitate
Interventions: Drug: Fibrinogen concentrate;   Drug: Cryoprecipitate
37 Completed Trial of NovoSeven® in Haemophilia - Joint Bleeds
Conditions: Congenital Bleeding Disorder;   Haemophilia A With Inhibitors;   Haemophilia B With Inhibitors
Interventions: Drug: activated recombinant human factor VII;   Drug: Feiba VH
38 Completed Anfibatide Phase 1 Clinical Trial in Healthy Volunteers
Conditions: Coronary Heart Disease;   Coagulation Disorder
Intervention: Drug: Anfibatide
39 Recruiting Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: NNC 0129-0000-1003
40 Completed A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A
Conditions: Congenital Bleeding Disorder;   Haemophilia A
Intervention: Drug: turoctocog alfa

Show previous page of results Previous Page (1-20) Studies Shown (21-40) Next Page (41-60) Show next page of results
Indicates status has not been verified in more than two years